April 21, 2026
PRMT5 Metabolomics Panel for Patient Stratification This poster presents a targeted, multiplexed LC-MS/MS metabolomics assay developed to support patient stratification and pharmacodynamic monitoring for MTA-cooperative PRMT5 inhibitors in oncology research. Leveraging Panome Bio’s specialized PRMT5 metabolomics panel, the assay enables sensitive and quantitative measurement of key metabolites associated with methylthioadenosine (MTA) biology and PRMT5 pathway […]
April 21, 2026
Decoding Alzheimer’s Disease with Multi-Omics Alzheimer’s disease involves coordinated changes across metabolism, proteins and cellular systems. By combining metabolomics and proteomics, this study examines how these changes relate within the same biological context.
April 15, 2026
This study presents an integrated proteomics and metabolomics analysis of Alzheimer’s disease using serum samples. Across 11,000+ molecular features, Panome Bio identified systemic metabolic dysregulation, lipid transport disruption, and protein-level changes associated with disease pathology.
March 31, 2026
Metabolomics Comparison: A Head-to-Head Study Panome Bio conducted a controlled head-to-head metabolomics study using identical samples analyzed by a legacy library-based platform and Next-Generation Metabolomics®️. The results show a nearly 4× increase in detected compounds, significantly broader pathway coverage, improved reproducibility and complete data matrices. This comparison highlights the limitations of traditional metabolomics workflows and […]
March 25, 2026
Pinpointing the Pervasive: Exposomics Analysis of Alzheimer’s Disease This poster presents a comprehensive exposomics analysis of Alzheimer’s disease, leveraging both targeted and discovery workflows to characterize environmental exposures and their biological impact. By capturing a broad spectrum of exogenous compounds—including pollutants, dietary components, pharmaceuticals, and microbiome-derived metabolites—this work highlights the critical role of the exposome […]
March 2, 2026
Exposomics Measuring Chemical Drivers of Human Disease Panome Bio’s Exposomics platform enables comprehensive measurement of chemical exposures that drive human disease. Using integrated discovery (32,000+ compounds) and targeted profiling (235 priority chemicals), we detect and quantify exogenous exposures at trace levels. Demonstrated in Alzheimer’s disease, our workflow reveals disease-associated environmental signatures with high sensitivity and […]
February 26, 2026
Our partners at Indiana University leveraged Next-Generation Metabolomics to profile metabolic and lipidomic changes in gingival crevicular fluid from healthy individuals and patients with periodontitis. Using dual LC-MS platforms and deep-learning–assisted data curation, the study identified 256 differentially expressed metabolites, revealing elevated purine degradation products, increased ceramides, reduced oxy-fatty acids, and enrichment of known periodontitis […]
February 25, 2026
Advancing Untargeted Metabolomics Data Analysis with MassID™ MassID™ is Panome Bio’s identification engine for Next-Generation Metabolomics®, designed to turn complex untargeted metabolomics data into confident metabolite identifications. By evaluating detected signals against a reference database of over 280,000 compounds and assigning quantitative confidence scores, MassID supports broader pathway analysis and reproducible biological conclusions.
February 24, 2026
MassID™ Turning Untargeted Data into Confident Discoveries Get a quick overview of how MassID enhances Panome Bio’s true untargeted metabolomics by transforming raw LC-MS/MS data into high-confidence, biologically interpretable metabolite profiles using advanced, probability-based identification.
February 19, 2026
MassID is a computational tool that enables near-complete annotation of untargeted metabolomics datasets by assigning identification probabilities to detected features. Traditional workflows often leave many metabolites unannotated, limiting downstream biological interpretation. MassID overcomes these limitations, improving confidence in metabolite identification and supporting research in systems biology, biomarker discovery, and metabolomics-driven insights. MassID, Panome Bio’s identification […]
